Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Enjoy The Back And Forth Guys
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2401)
•••
Comment by JDavenporton Dec 15, 2022 8:52pm
175 Views
Post# 35174829

RE:RE:RE:RE:RE:RE:RE:Enjoy The Back And Forth Guys

RE:RE:RE:RE:RE:RE:RE:Enjoy The Back And Forth GuysAlso, narmac, there have been a couple that I have not spoken to but have spoken to people I talked to myself. I have not spoken to chrispi, for instance, who, other than a certain broker, probably controls and influences more shares than anyone. Huge! I wish I could describe him fully, here.

I can't imagine him being too happy, or the many people in his camp.

I forgot to mention the Stockhouse personal messages. I have received PMs from four shareholders, making it about 16 in total who have communicated with me. I think they may represent 10 million  or more shares.

And then there are dozens on here who are reading my posts, many of whom are obviously not happy and have expressed it here.

There has been no apparent support for this at all. 

I mean, 7 cents. Who would be happy about that?

A strategy may come out of it, but some may just want to go away and ignore things, which is a yes vote for DrDR in the AGM and in a special meeting.

jd
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities